MaaT Pharma S.A.
MAAT.PA · PAR
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.13 | -0.16 | 0.09 | 0.04 |
| FCF Yield | -21.92% | -24.91% | -16.77% | -25.21% |
| EV / EBITDA | -3.79 | -3.13 | -4.22 | 0.60 |
| Quality | ||||
| ROIC | -93.63% | -57.20% | -35.23% | -19.35% |
| Gross Margin | 61.13% | 35.19% | 76.29% | 82.92% |
| Cash Conversion Ratio | 0.76 | 0.95 | 0.92 | 0.88 |
| Growth | ||||
| Revenue 3-Year CAGR | 31.02% | 31.85% | – | 121.61% |
| Free Cash Flow Growth | -15.34% | -48.96% | -62.45% | -33.23% |
| Safety | ||||
| Net Debt / EBITDA | 0.16 | 0.46 | 1.82 | 4.38 |
| Interest Coverage | -32.75 | -48.29 | -67.44 | -73.50 |
| Efficiency | ||||
| Inventory Turnover | 19.53 | 7.60 | 7.21 | 5.03 |
| Cash Conversion Cycle | -2,386.96 | -710.82 | -4,534.82 | 1,314.73 |